What the research found

Researchers identified a mechanism by which the brain's immune cells (microglia) mistakenly attack living neurons in ALS. Normally, microglia use a recognition system called TAM signaling to identify and clear genuinely dead cells—cells display a lipid called phosphatidylserine on their surface as an "eat me" signal. In ALS, this system becomes corrupted: microglia upregulate TAM receptors (particularly AXL and MER), while motor neurons begin displaying the death signal even though they remain metabolically alive and are not undergoing programmed cell death.

The team demonstrated this in human tissue samples and mouse models of ALS. They found that neurons showing the "eat me" signal lacked markers of actual apoptosis, meaning microglia were responding to a false alarm. When researchers genetically removed AXL and MER from microglia in adult disease-stage mice, they observed roughly a threefold preservation of motor neurons and extended survival by several weeks, with improved neuromuscular connections and muscle preservation.

Why it matters for you

This work suggests that blocking microglial TAM signaling could potentially slow motor neuron loss in ALS—a disease currently without effective disease-modifying treatments. If this translates to humans, it might represent a therapeutic angle distinct from most current approaches, which focus on what goes wrong inside neurons themselves.

For health-optimizers tracking biomarkers, this highlights why inflammatory markers (like those reflecting microglial activation) and immune balance matter beyond infection control. The researchers note the therapeutic appeal: rather than complex cell-based immunotherapies, small-molecule inhibitors targeting TAM proteins could be administered systemically. The finding also underscores that neuroinflammation isn't always harmful—blocking the wrong pathway too early triggered earlier disease signs in mice—suggesting any intervention would need careful timing and specificity.

Caveats

• Primarily mouse work: Core findings come from genetically modified mice; human validation is limited to postmortem tissue samples (n=6 ALS, 3 controls).
• Early-stage disease model: SOD1G93A mice model familial ALS, not the more common sporadic form affecting most patients.
• Germline vs. inducible deletion: The initial knockout existed from birth, confounding interpretation; the cleaner tamoxifen-induced adult deletion showed similar but somewhat attenuated benefits.
• TAM system complexity: TAM signaling regulates immune homeostasis broadly; systemic inhibition triggered earlier autoimmune complications, suggesting off-target toxicity risk in translation.
• Mechanistic gap: The study identifies that neurons display the death signal but not why—the upstream trigger remains unclear.